American Cancer Society Consumer's Guide to Cancer Drugs, Second Edition (Jones and Bartlett Series in Oncology) [Paperback]

Gail Wilkes (Author)

Book Description

ISBN-10: 0763722545 | ISBN-13: 978-0763722548 | Publication Date: April 2003 | Edition: 2 Sub

Current knowledge of the drugs used in cancer care is critical for today's practicing nurse. Drugs covered are described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations. Potential toxicities, side effects, and the nursing process are detailed.

Product Details

• Paperback: 535 pages
• Publisher: Jones and Bartlett Publishers, Inc.; 2 Sub edition (April 2003)
• Language: English
• ISBN-10: 0763722545
• ISBN-13: 978-0763722548
• Product Dimensions: 9 x 6 x 1.1 inches
• Shipping Weight: 1.7 pounds (View shipping rates and policies)
• Average Customer Review: 1.0 out of 5 stars  See all reviews (1 customer review)
• Amazon Best Sellers Rank: #1,398,601 in Books (See Top 100 in Books)

More About the Author

Discover books, learn about writers, read author blogs, and more.

Customer Reviews

Most Helpful Customer Reviews

4 of 12 people found the following review helpful:

1.0 out of 5 stars Biased report in favor of Big Pharma, December 2, 2004

By 

Patricia Joy (CA) - See all my reviews

This review is from: American Cancer Society Consumer's Guide to Cancer Drugs, Second Edition (Jones and Bartlett Series in Oncology) (Paperback)

I would never trust anything the American Cancer Society says. They are very biased in favor of expensive pharmaceuticals with cancer-causing side-effects. They are the wealthiest "charity" in America, with cash reserves of $1 Billion.

The Role of the ACS in the War Against Cancer

The verdict is unassailable. The American Cancer Society bears a major responsibility for losing the winnable war against cancer.
The launching of the 1971 War Against Cancer provided the ACS with a well-exploited opportunity to pursue it own myopic and self-interested agenda. Its strategies remain based on two lies -- that there has been dramatic progress in the treatment and cure of cancer, and that any increase in the incidence and mortality of cancer is due to aging of the population and smoking while denying any significant role for involuntary exposures to industrial carcinogens in air, water, consumer products and the workplace.

Most of the funds raised by ACS go to pay overhead, salaries, fringe benefits, and travel expenses of its national executives in Atlanta. They also go to pay Chief Executive Officers, who earn six-figure salaries in several states, and the hundreds of other employees who work out of some 3,000 regional offices nationwide. The typical ACS affiliate, which helps raise the money for the national office, spends more than 52 percent of its budget on salaries, pensions, fringe benefits, and overhead for its own employees.

Salaries and overhead for most ACS affiliates also exceeded 50 percent, although most direct community services are handled by unpaid volunteers. DiLorenzo summed up his findings by emphasizing the hoarding of funds by the ACS.

"Most contributors believe their donations are being used to fight cancer, not to accumulate financial reserves. More progress in the war against cancer would be made if they would divest some of their real estate holdings and use the proceeds -- as well as a portion of their cash reserves -- to provide more cancer services."

Aside from high salaries and overhead, most of what is left of the ACS budget goes to basic research and research into profitable, patented cancer drugs.

The current budget of the ACS is $380 million and its cash reserves approach one billion dollars. Yet its aggressive fund-raising campaign continues to plead poverty, and lament the lack of available money for cancer research, while ignoring efforts to prevent cancer by phasing out avoidable exposures to environmental and occupational carcinogens.

Meanwhile, the ACS is silent about its intricate relationships with the wealthy cancer drug industry and chemical industries.

Read more....... http://www.corporations.org/cancer/boycottacs.html